Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Burden of PCOS
4.2.2 Growth in Initiatives by Government and Private Players to Raise Awareness
4.3 Market Restraints
4.3.1 Adverse Effects Associated with Treatment
4.3.2 Lack of FDA Approved Drugs Specific to Polycystic Ovarian Syndrome (PCOS)
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Treatment
5.1.1 Drug Class
5.1.1.1 Contraceptives
5.1.1.2 Insulin-sensitizing Agent
5.1.1.3 Antidepressants
5.1.1.4 Anti-obesity
5.1.1.5 Others
5.1.2 Surgery
5.1.2.1 Ovarian Wedge Resection
5.1.2.2 Laparoscopic Ovarian Drilling
5.1.2.3 Other Surgeries
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 France
5.2.2.2 Germany
5.2.2.3 United Kingdom
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 AstraZeneca PLC
6.1.3 Bayer AG
6.1.4 Takeda Pharmaceutical Company Limited
6.1.5 Ferring BV
6.1.6 Merck KGaA
6.1.7 Novartis International AG
6.1.8 Pfizer Inc.
6.1.9 Sanofi SA
6.1.10 Teva Pharmaceutical Industries Limited


7 MARKET OPPORTUNITIES AND FUTURE TRENDS